WO2021023952A1 - Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium - Google Patents

Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium Download PDF

Info

Publication number
WO2021023952A1
WO2021023952A1 PCT/FR2020/051445 FR2020051445W WO2021023952A1 WO 2021023952 A1 WO2021023952 A1 WO 2021023952A1 FR 2020051445 W FR2020051445 W FR 2020051445W WO 2021023952 A1 WO2021023952 A1 WO 2021023952A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cosmetic
skin
angustifolium
advantageously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2020/051445
Other languages
English (en)
French (fr)
Inventor
Anabelle ECHARD
Florence Henry
Nicolas Pelletier
Sabine Pain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
Original Assignee
BASF Beauty Care Solutions France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF Beauty Care Solutions France SAS filed Critical BASF Beauty Care Solutions France SAS
Priority to ES20757653T priority Critical patent/ES3008702T3/es
Priority to JP2022507337A priority patent/JP7741060B2/ja
Priority to EP20757653.9A priority patent/EP4009940B1/fr
Priority to CN202080055594.XA priority patent/CN114206310A/zh
Priority to KR1020227001622A priority patent/KR102909330B1/ko
Publication of WO2021023952A1 publication Critical patent/WO2021023952A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the skin pores are the orifices through which the secretions of the sebaceous and sweat glands flow. They contain a hair follicle and a sebaceous gland.
  • Various external factors such as UV radiation, heat, pollution but also poor hygiene or an unbalanced diet, and more simply skin aging, can contribute to the dilation of the pores, to make the skin less smooth and unsightly. The pores become visible and the resulting effect is unsightly.
  • intrinsic factors such as androgen hormones and growth factors modulate the activity of the sebaceous and sweat glands.
  • Application FR2890309 describes a cosmetic care process for reducing cutaneous imperfections of the skin comprising the application of three successive compositions, including a care composition which may comprise a soothing agent such as an extract of E angustifolium.
  • a care composition which may comprise a soothing agent such as an extract of E angustifolium.
  • this extract is described in a long list of soothing agents.
  • an ingredient that is active on the sebum which is secreted by the sebaceous glands and is characteristic of oily skin when present in excess, is distinguished from an ingredient that is active on the pores of the skin, advantageously. by regulation of hyperkeratinization.
  • a first object of the invention thus relates to the cosmetic, non-therapeutic use of an extract of E angustifolium for reducing the visibility of the pores of the skin and / or preventing its increase.
  • Another subject relates to said use in a cosmetic composition comprising at least one cosmetically acceptable excipient.
  • Another subject still relates to a cosmetic care process comprising the topical or oral administration of the extract of E angustifolium according to the invention or of a cosmetic composition comprising it.
  • the use of the extract can be orally or topically.
  • it is by the topical route.
  • topical route is understood to mean direct local application and / or spraying of the ingredient onto the surface of the skin and / or of the mucous membranes.
  • the skin does not include the scalp.
  • reducing the visibility of the pores of the skin is understood to mean reducing the diameter of the opening and / or the area and / or the density of the skin pores.
  • the visibility of the pores of the skin can be demonstrated in vivo by a so-called “scoring” evaluation by a dermatologist on a predefined area after application of a composition comprising the extract according to the invention. It can also be demonstrated by an objective instrumental method by an image analysis which makes it possible to extract and quantify specific parameters of high-resolution photographs in cross-polarized configuration of the face of volunteers before and after application of a composition comprising the extract according to the invention.
  • the density of the skin pores can also be measured in vivo by imaging, in particular by the fringe projection technique, by measuring the so-called curvature parameter.
  • the extract according to the invention decreases the visibility of the pores of the skin by reducing the hyperkeratinization of the skin.
  • hyperkeratinization is understood to mean hyperproliferation of the keratinocytes, without this being a pathology requiring pharmaceutical treatment, in particular dermatological treatment.
  • reducing hyperkeratinization can mean increasing the gene and / or protein expression of IGFBP3.
  • the extract according to the invention is in an amount effective to maintain and / or increase the gene and / or protein expression of IGFBP3 when the expression of IGBF3 is increased by at least 60%, advantageously of 'at least 80%, still advantageously at least 100%, and very advantageously at least 150% in the presence of the extract according to the invention, in comparison with the level of expression detected in the absence of said extract.
  • this measurement is carried out in normal keratinocytes cultured in the presence of the extract of E angustifolium, preferably as prepared according to example la), very advantageously again at a concentration of 0.05% by weight relative to to the final volume of the culture medium, in particular by the method described under the conditions of Example 2a).
  • decreasing hyperkeratinization can also mean increasing the gene and / or protein expression of type IV collagen.
  • the extract of E angustifolium according to the invention is considered to be in an amount effective for maintaining and / or increasing the gene and / or protein expression of type IV collagen when the gene and / or protein expression of type IV collagen.
  • IV is increased by at least 40%, preferably by at least 80%, more preferably by at least 120%, and very preferably by at least 150% in the presence of the extract according to the invention, compared to level of expression detected in the absence of said extract.
  • the measurement of the visibility of the pores of the skin could also be evaluated in vivo.
  • the extract of E angustifolium according to the invention is considered to be in an effective amount for “reducing the visibility of the pores of the skin and / or preventing its increase” when the extract decreases by at least 5%, advantageously at least 8%, the visibility of pores of the skin in the presence of the extract according to the invention, in comparison with the visibility of pores evaluated without extract.
  • the measurement of the visibility of the pores is evaluated by a specialist dermatologist, in a population for which has been applied topically to their hemi-face a cosmetic formulation comprising the extract of E angustifolium according to the invention, the second part of the face serving as a control.
  • the cosmetic formulation comprises a final concentration by weight of 0.20% relative to the total weight of said formulation, of the extract tested may be an extract of E angustifolium according to example la), and it may be tested under the conditions described in Example 3.
  • the extract according to the invention can be an extract of all or part of the E. angustifolium plant chosen from the leaves, the flower, the petals, the seed, the stem and / or the aerial parts.
  • the term “aerial parts” is understood here to mean a mixture of leaves, flowers and stems.
  • the extract according to the invention is an extract comprising the aerial parts and very advantageously, it is an extract containing only the aerial parts.
  • the extraction can be carried out from dry or fresh material, advantageously dry, in an amount of 0.1% to 20% by weight, advantageously from 1% to 20%, very advantageously from 5% to 15%, and even more advantageously 15% by weight relative to the total weight of the material and of the extraction solvent.
  • dry matter is understood to mean a dehydrated plant material comprising less than 15%, advantageously less than 10%, still advantageously less than 5% and very advantageously less than 1% of water.
  • subcritical conditions extraction is understood to mean extraction in the presence of water, under conditions of temperature above 100 ° C. and pressure below 221 bars, such that the water remains in the liquid state but has a viscosity. and a surface tension lower than that of water at room temperature, increasing its dielectric constant.
  • the extract according to the invention can be obtained by extraction in a solvent or mixture of solvent, preferably a polar protic solvent, and advantageously in water, an alcohol, a glycol, a polyol, a water / alcohol mixture, water / glycol or water / polyol (such as water mixed with ethanol, glycerol and / or butylene glycol and / or other glycols such as xylitol and / or propanediol, etc.) from 99/1 to 1/99 (w / w ), advantageously in water as the sole solvent.
  • solvent or mixture of solvent preferably a polar protic solvent
  • the extract according to the invention is present in the cosmetic or dermatological composition at a concentration of 1 x 10 4 % to 10%, preferably 1 x 10 4 % to 5%, more preferably 1 x 10 3 % to 3% by weight, and very preferably from 1 ⁇ 10 3 % to 0.1% relative to to the total weight of the composition.
  • the extract, in particular that prepared according to example la) is present at a concentration of 0.05% by weight relative to the total weight of the composition.
  • the extract, in particular that prepared according to example la is present at a concentration of 0.125xl0 2 % or of 0.25xl0 2 % by weight relative to the total weight of the mixture. composition.
  • the cosmetic composition may also comprise other cosmetic active ingredients.
  • Many cosmetically active ingredients are known to those skilled in the art to improve the health and / or the physical appearance of the skin.
  • the compounds described in the present invention can have a synergistic effect when they are combined with each other. These combinations are also covered by the present invention.
  • the CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industry, which are in particular suitable for topical use. Examples of these classes of ingredients include, without being limited thereto, the following compounds: abrasive, absorbents, cosmetic compound such as perfumes, pigments, dyes, essential oils, astringents, for example olive oil.
  • the cosmetic composition containing the extract according to the invention will contain another sebum-regulating agent chosen from sarcosine and an extract of Orthosiphon stamineus, an extract of Bixa orellana, zinc gluconate and their mixtures, a moisturizing agent chosen from a Cassia angustifolia seed extract, hexosyl glyceride, a mixture containing pullulan, sodium hyaluronate and sodium alginate, and mixtures thereof.
  • another sebum-regulating agent chosen from sarcosine and an extract of Orthosiphon stamineus, an extract of Bixa orellana, zinc gluconate and their mixtures
  • a moisturizing agent chosen from a Cassia angustifolia seed extract, hexosyl glyceride, a mixture containing pullulan, sodium hyaluronate and sodium alginate, and mixtures thereof.
  • the cosmetic care process comprises the topical application of the extract according to the invention or of a cosmetic composition comprising it on all or part of the body and / or the face, advantageously chosen from the legs, feet, armpits, hands, thighs, stomach, Vietnameselleté, neck, arms, torso, back, face and / or scalp, more advantageously the scalp and / or the face, even more advantageously the face.
  • a cosmetic formulation comprising the extract of E angustifolium as prepared in example la) at a final concentration by weight of 0.20% relative to the total weight of the cosmetic formulation, was applied twice a day during a period of 56 days on the half-face of a human population of 34 females of Asian origin aged 20 to 45 years.
  • the same cosmetic formulation comprising water in place of the extract of E angustifolium (Control) was applied under the same conditions to the other half-face of the same population.
  • the measurements were taken at times D0 and D56 (56 days).
  • a specialist in the field that is to say a dermatologist, evaluated the hemi-faces of the 34 people to whom the cosmetic formulation was applied, in comparison with those to which the control formulation was applied.
  • the results of measurement of the area of the skin pores are shown in Table III below.
  • Glycerin 80% Example 5 Cosmetic formulation comprising an extract of f. angustifolium according to the invention

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/FR2020/051445 2019-08-08 2020-08-06 Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium Ceased WO2021023952A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES20757653T ES3008702T3 (en) 2019-08-08 2020-08-06 New cosmetic use of an extract of epilobium angustifolium
JP2022507337A JP7741060B2 (ja) 2019-08-08 2020-08-06 ヤナギラン(Epilobium angustifolium)抽出物の新規な化粧用使用
EP20757653.9A EP4009940B1 (fr) 2019-08-08 2020-08-06 Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium
CN202080055594.XA CN114206310A (zh) 2019-08-08 2020-08-06 柳兰提取物的新型化妆品用途
KR1020227001622A KR102909330B1 (ko) 2019-08-08 2020-08-06 분홍바늘꽃 추출물의 신규 화장료 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1909079A FR3099702B1 (fr) 2019-08-08 2019-08-08 Nouvelle utilisation cosmétique d’un extrait d’Epilobium angustifolium
FR1909079 2019-08-08

Publications (1)

Publication Number Publication Date
WO2021023952A1 true WO2021023952A1 (fr) 2021-02-11

Family

ID=68807060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2020/051445 Ceased WO2021023952A1 (fr) 2019-08-08 2020-08-06 Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium

Country Status (7)

Country Link
EP (1) EP4009940B1 (cg-RX-API-DMAC7.html)
JP (1) JP7741060B2 (cg-RX-API-DMAC7.html)
KR (1) KR102909330B1 (cg-RX-API-DMAC7.html)
CN (1) CN114206310A (cg-RX-API-DMAC7.html)
ES (1) ES3008702T3 (cg-RX-API-DMAC7.html)
FR (1) FR3099702B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021023952A1 (cg-RX-API-DMAC7.html)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR654316A (fr) 1927-06-30 1929-04-04 Ig Farbenindustrie Ag Procédé pour la fabrication de dérivés d'hydrocarbures et d'hydrocarbures non saturés
FR2831440A1 (fr) 2001-10-25 2003-05-02 Oreal Composition cosmetique, renfermant un derive de la dhea et un agent apaisant
CA2386648A1 (en) 2002-05-16 2003-11-16 Fytokem Products Inc. Compositions and methods for managing bacterial skin conditions
JP2003342154A (ja) 2002-05-28 2003-12-03 Noevir Co Ltd 皮膚外用剤
WO2004016236A1 (ja) 2002-08-14 2004-02-26 Fancl Corporation 化粧料
FR2855968A1 (fr) 2003-06-13 2004-12-17 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
EP1119344B1 (fr) 1998-10-05 2004-12-22 Laboratoires Expanscience Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie
FR2890309A1 (fr) 2005-09-05 2007-03-09 Oreal Procede cosmetique de soin des peaux grasses et kit associe
FR2893252A1 (fr) 2005-11-17 2007-05-18 Engelhard Lyon Sa Extraits vegetaux stimulant has2
WO2014027163A2 (fr) 2012-08-13 2014-02-20 Basf Beauty Care Solutions France Sas Ingredient hydratant cosmetique ou pharmaceutique
US20160184216A1 (en) 2013-08-22 2016-06-30 Lucas Meyer Cosmetics Canada Inc. Anti-dandruff compositions, and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003277249A (ja) 2002-03-20 2003-10-02 Noevir Co Ltd 皮膚外用剤、並びに表皮細胞賦活剤,真皮線維芽細胞賦活剤,コラーゲン産生促進剤
KR100844277B1 (ko) 2005-04-29 2008-07-07 (주)아모레퍼시픽 히드록삼산 유도체 및 이의 제조방법
KR100921971B1 (ko) * 2007-10-24 2009-10-15 한국과학기술연구원 블루밍샐리 추출물을 유효성분으로 함유하는 조성물
JP2011121879A (ja) 2009-12-09 2011-06-23 Kao Corp 毛穴目立ち予防又は改善剤
JP5791879B2 (ja) 2010-06-22 2015-10-07 三省製薬株式会社 NF−κB活性化抑制剤ならびに毛穴ケア剤
KR101877801B1 (ko) 2012-07-05 2018-07-13 (주)아모레퍼시픽 수경재배 인삼 유래 진세노사이드 f2를 함유하는 피부 외용제 조성물
JP6175280B2 (ja) 2013-05-22 2017-08-02 ピアス株式会社 毛穴改善用組成物
US10765621B2 (en) * 2013-09-22 2020-09-08 Symrise Ag Extracts of halimione portulacoides and their application
FR3011469B1 (fr) * 2013-10-08 2017-11-10 Basf Beauty Care Solutions France Sas Utilisation cosmetique et/ou dermatologique d'un extrait d'hamamelis virginiana
WO2016060298A1 (ko) 2014-10-15 2016-04-21 주식회사 아모레퍼시픽 Abh 항원의 발현을 조절하는 물질을 포함하는 조성물
CN106265392A (zh) * 2016-11-07 2017-01-04 北京痘博士痤疮医学研究院 一种康肤净化精华液
CN109602773A (zh) 2019-01-31 2019-04-12 中国科学院西北高原生物研究所 一种具有抗氧化作用的组合物及其制备方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR654316A (fr) 1927-06-30 1929-04-04 Ig Farbenindustrie Ag Procédé pour la fabrication de dérivés d'hydrocarbures et d'hydrocarbures non saturés
EP1119344B1 (fr) 1998-10-05 2004-12-22 Laboratoires Expanscience Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie
FR2831440A1 (fr) 2001-10-25 2003-05-02 Oreal Composition cosmetique, renfermant un derive de la dhea et un agent apaisant
CA2386648A1 (en) 2002-05-16 2003-11-16 Fytokem Products Inc. Compositions and methods for managing bacterial skin conditions
JP2003342154A (ja) 2002-05-28 2003-12-03 Noevir Co Ltd 皮膚外用剤
WO2004016236A1 (ja) 2002-08-14 2004-02-26 Fancl Corporation 化粧料
FR2855968A1 (fr) 2003-06-13 2004-12-17 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
FR2890309A1 (fr) 2005-09-05 2007-03-09 Oreal Procede cosmetique de soin des peaux grasses et kit associe
FR2893252A1 (fr) 2005-11-17 2007-05-18 Engelhard Lyon Sa Extraits vegetaux stimulant has2
WO2014027163A2 (fr) 2012-08-13 2014-02-20 Basf Beauty Care Solutions France Sas Ingredient hydratant cosmetique ou pharmaceutique
US20160184216A1 (en) 2013-08-22 2016-06-30 Lucas Meyer Cosmetics Canada Inc. Anti-dandruff compositions, and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Cosmetic Ingrédient Handbook", 1992, LE CTFA
DATABASE GNPD [online] MINTEL; 4 August 2010 (2010-08-04), ANONYMOUS: "Luminizing Black Mask", XP055683370, retrieved from www.gnpd.com Database accession no. 1379982 *
INTERNET CITATION, 5 February 2004 (2004-02-05), XP002269178, Retrieved from the Internet <URL:http://www.dweckdata.com/Lectures/SCS_Nov_1992.pdf> [retrieved on 20040205] *

Also Published As

Publication number Publication date
FR3099702B1 (fr) 2022-03-25
KR20220044488A (ko) 2022-04-08
JP7741060B2 (ja) 2025-09-17
EP4009940A1 (fr) 2022-06-15
ES3008702T3 (en) 2025-03-24
JP2022543141A (ja) 2022-10-07
EP4009940B1 (fr) 2024-10-30
KR102909330B1 (ko) 2026-01-07
CN114206310A (zh) 2022-03-18
FR3099702A1 (fr) 2021-02-12

Similar Documents

Publication Publication Date Title
EP3618802B1 (fr) Utilisation d&#39;un extrait de nephelium lappaceum pour augmenter la fermeté de la peau et/ou des muqueuses
FR2975495A1 (fr) Methode de criblage de principes actifs favorisant la deglycation des ages
WO2019025725A1 (fr) Utilisation d&#39;un extrait de péricarpe de nephelium lappaceum pour hydrater la peau et/ou les muqueuses
EP3203981B1 (fr) Activite deglycation d&#39;une combinaison d&#39;un extrait de salvia miltiorrhiza et de niacine et/ou de niacinamide
WO2020128223A1 (fr) Nouvelles utilisations cosmétiques et dermatologiques d&#39;un extrait de cistus monspeliensis
FR2928548A1 (fr) Substances augmentant le seuil d&#39;activation des cellules immunes
EP3541478B1 (fr) Utilisation cosmétique, nutraceutique ou pharmaceutique préférentiellement dermatologique d&#39;un extrait de feuilles de la plante lansium domesticum pour diminuer la pigmentation de la peu et/ou des annexes cutanées
EP3801778B1 (fr) Utilisation d&#39;un extrait de bixa orellana
EP3237072B1 (fr) Utilisation d&#39;un extrait de lythrum salicaria
FR3135899A1 (fr) Utilisation cosmétique ou dermatologique d’un extrait de Dendrobium officinale pour maintenir et/ou augmenter l’épaisseur de la peau
WO2019025724A1 (fr) Nouvelle utilisation cosmetique d&#39;un extrait de nephelium lappaceum
EP2896430A1 (fr) Utilisation cosmétique ou dermatologique d&#39;un extrait de Quassia amara
EP4009940B1 (fr) Nouvelle utilisation cosmétique d&#39;un extrait d&#39;epilobium angustifolium
WO2023180661A1 (fr) Utilisation cosmetique ou dermatologique d&#39;un extrait de dendrobium officinale pour maintenir et/ou augmenter l&#39;epaisseur de la peau
FR3061015B1 (fr) Utilisation cosmetique d&#39;un extrait de corchorus olitorius
WO2021152250A1 (fr) Utilisation cosmétique, nutraceutique ou dermatologique d&#39;un extrait de tamarindus indica l. et / ou d&#39;une composition le comprenant
CH694904A5 (fr) Utilisation d&#39;un extrait de Rhodiola crenulata, par voie topique.
FR3076734A1 (fr) Nouvelle utilisation cosmetique d&#39;un extrait de nephelium lappaceum
FR3099701A1 (fr) Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide
FR3103386A1 (fr) Nouvelle utilisation cosmétique d’un extrait glycoprotéique de Prunus dulcis
WO2025062101A1 (fr) Extrait de citrus aurantium et son utilisation en tant qu&#39;agent cosmetique
FR3052358A1 (fr) Nouvelle utilisation d&#39;un extrait d&#39;orthosiphon stamineus
FR3082747A1 (fr) Utilisation cosmetique ou pharmaceutique d&#39;un extrait de grindelia robusta

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20757653

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022507337

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020757653

Country of ref document: EP

Effective date: 20220309